DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

4574 '99 JUN 22 AID:37

Date:

June 14, 1999

To:

Dockets Management Branch (HFA-305)

From:

Ted Sherwood

Management Analyst

Office of Generic Drugs

Subject:

Presentation Regarding Human Generic Drugs to Docket

90S-0308

This memorandum forwards overheads of a presentation to the Dockets Management Branch for inclusion in Docket 90S-0308. The following is information on the presentation for the Docket records:

Title of Presentation:

Regulatory Harmonization Friend or Foe?

Presented for:

International Generic Pharmaceutical

Association

Date Presented:

June 3, 1999

Presented by:

Douglas L. Sporn

York Marion

Number of Pages:

17

Attachment

M642

905-0308

International Generic Pharmaceutical Association

Regulatory Harmonization Friend or Foe?

Douglas L. Sporn
Director, Office of Generic Drugs
U.S. Food & Drug Administration
June 3, 1999
Barcelona, Spain

The answer depends on where you sit.

 Multinational Firms vs. "Mom & Pop" Firms


Industry vs. National Regulators

Other Titles:

Harmonization: Winding Up or Winding Down?

Harmonization: You Ain't Seen Nothing Yet!!

International Trade Harmonization



FDA Scientific & Regulatory Harmonization

Office of Generic Drugs (OGD)

Chemistry, Manufacturing & Control Coordinating Committee (CMCCC)

Office of New Drug Chemistry (ONDC)


Office of Pharmaceutical Science (OPS)

Biopharmaceutics Coordinating Committee (BCC)


Complex Drug Substances Coordinating Committee (CDSCC)

Food & Drug Administration Modernization Act (FDAMA)


Pre-OPS Reviewing Organizations




Office of Pharmaceutical Science




Chemistry, Manufacturing and Controls Coordinating Committee



Complex Drug Substances, Excipients, and Reagents Coordinating Committee



Biopharmaceutics Coordinating Committee



International Regulatory Harmonization

International Conference on Harmonization (ICH)

International Conference of Drug Regulatory Authorities/WHO

Steering Committee for the Pan American Conferences on Drug Regulatory Harmonization

PAHO



International International . FDA Scientific & Trade Regulatory Regulatory Harmonization Harmonization Harmonization **ICH GATT OGD** International **CMCCC** URAA Conference of Drug **ONDC** Regulatory **TRIPS Authorities/WHO OPS** WTO **Steering Committee** for Pan American BCC **TransAtlantic** Conference on Drug **Business Dialog** Regulatory **FDAMA** Harmonization

Harmonization

Friend?

Foe?

Predictability

The Devil is in the Details!

Public Resource Savings (long term) Public Resource Costs (short term)

Optimization of World Resources

Harmonization

Friend?

Foe?

Competition

Competition

Lower "Break Even"
Point

Higher "Break Even" Point

Reduces Some Market Barriers Increases Market Barrier

Harmonization

Friend?

Levels the Playing Field

>More Ethical

>World Citizen

Better Science

Availability of More Products/Faster

Foe?

Unnecessarily Elevates the Playing Field

Not That Much Better!

More Difficult to Change Policy

The Decade Ahead

- ICH -- Moves to harmonize on more quality topics for NME's and Generics
 - Process modified to make generics "official" members
- Americas -- Trend to modern quality standards for generic drugs accelerates
 - WHO -- Continues to move lesser developed countries toward better, universally accepted quality standards